Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Panbela Therapeutics, Inc. < Previous 1 2 Next > First Patient Enrolled in Phase I Program in STK11 Mutant Non-Small Cell Lung Cancer at Moffitt Cancer Center September 24, 2024 From Panbela Therapeutics, Inc. Via GlobeNewswire Tickers PBLA Panbela to Host Second Quarter 2024 Earnings Conference Call on Aug 13, 2024 July 30, 2024 From Panbela Therapeutics, Inc. Via GlobeNewswire Tickers PBLA Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification June 24, 2024 From Panbela Therapeutics, Inc. Via GlobeNewswire Tickers PBLA Panbela Announces Oral Presentation at Digestive Disease Week (DDW): June 10, 2024 From Panbela Therapeutics, Inc. Via GlobeNewswire Tickers PBLA Panbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and Sulindac May 06, 2024 From Panbela Therapeutics, Inc. Via GlobeNewswire Tickers PBLA Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024 May 01, 2024 From Panbela Therapeutics, Inc. Via GlobeNewswire Tickers PBLA Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease Week April 30, 2024 From Panbela Therapeutics, Inc. Via GlobeNewswire Tickers PBLA Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025 April 22, 2024 From Panbela Therapeutics, Inc. Via GlobeNewswire Tickers PBLA Panbela Announces Poster Presentation at American Association for Cancer Research: April 18, 2024 From Panbela Therapeutics, Inc. Via GlobeNewswire Tickers PBLA Panbela Announces Transfer to OTCQB Market April 16, 2024 From Panbela Therapeutics, Inc. Via GlobeNewswire Tickers PBLA Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024 March 12, 2024 From Panbela Therapeutics, Inc. Via GlobeNewswire Tickers PBLA Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements February 15, 2024 From Panbela Therapeutics, Inc. Via GlobeNewswire Tickers PBLA Panbela Announces Closing of Approximately $9.0 Million Public Offering February 01, 2024 From Panbela Therapeutics, Inc. Via GlobeNewswire Tickers PBLA Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR) January 30, 2024 From Panbela Therapeutics, Inc. Via GlobeNewswire Tickers PBLA Panbela Announces Pricing of Approximately $9.0 Million Public Offering January 29, 2024 From Panbela Therapeutics, Inc. Via GlobeNewswire Tickers PBLA Panbela Exceeds 50% Enrollment for Aspire Trial in Pancreatic Cancer, Exceeding Anticipated Timelines with Accelerated Momentum January 25, 2024 From Panbela Therapeutics, Inc. Via GlobeNewswire Tickers PBLA Panbela Announces Publication of Clinical Data Titled: Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial January 18, 2024 From Panbela Therapeutics, Inc. Via GlobeNewswire Tickers PBLA Panbela Announces 1-for-20 Reverse Stock Split Effective January 18, 2024 January 16, 2024 From Panbela Therapeutics, Inc. Via GlobeNewswire Tickers PBLA Panbela Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $2.0 Million Gross Proceeds Priced At-the-Market December 21, 2023 From Panbela Therapeutics, Inc. Via GlobeNewswire Tickers PBLA Panbela Therapeutics Announces US WorldMeds NDA Approval for Eflornithine (DFMO) in Pediatric Neuroblastoma December 18, 2023 From Panbela Therapeutics, Inc. Via GlobeNewswire Tickers PBLA Panbela Announces Publication of Abstract Titled: Evaluation of Myeloma Cell Lines Viability Following Administration of SBP-101 and DFMO Polyamine Inhibitors December 04, 2023 From Panbela Therapeutics, Inc. Via GlobeNewswire Tickers PBLA Panbela Announces 2nd Independent Safety Review of the ASPIRE Registration Clinical Trial: Recommended Continuation with no Trial Modification November 29, 2023 From Panbela Therapeutics, Inc. Via GlobeNewswire Tickers PBLA Panbela Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.9 Million Gross Proceeds Priced At-the-Market November 03, 2023 From Panbela Therapeutics, Inc. Via GlobeNewswire Tickers PBLA Panbela Announces Publication of Preclinical and Clinical Data Titled: Inhibition of Polyamine Biosynthesis Preserves β Cell Function in Type 1 Diabetes November 02, 2023 From Panbela Therapeutics, Inc. Via GlobeNewswire Tickers PBLA Panbela Announces Validation of European Patent in UK, Italy, Germany, France, and Spain for Claims of a Novel Process for the Production of SBP-101 October 31, 2023 From Panbela Therapeutics, Inc. Via GlobeNewswire Tickers PBLA Acceptance of Polyamine Inhibitor CAR-T Combination Abstract for Online Publication October 25, 2023 From Panbela Therapeutics, Inc. Via GlobeNewswire Tickers PBLA Panbela to Host Third Quarter 2023 Earnings Conference Call on November 9, 2023 October 24, 2023 From Panbela Therapeutics, Inc. Via GlobeNewswire Tickers PBLA Panbela Announces Issuance of New Patent in China for Claims of a Novel Process for the Production of SBP-101 September 26, 2023 From Panbela Therapeutics, Inc. Via GlobeNewswire Tickers PBLA Panbela to Present at the LD Micro Investor Conference September 19, 2023 From Panbela Therapeutics, Inc. Via GlobeNewswire Tickers PBLA Panbela Announces Issuance of New Patent in Chile for Claims of a Novel Process for the Production of Flynpovi September 05, 2023 From Panbela Therapeutics, Inc. Via GlobeNewswire Tickers PBLA < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.